Business Daily from THE HINDU group of publications
Saturday, Sep 20, 2008
ePaper | Mobile/PDA Version | Audio
Business Daily from THE HINDU group of publications Saturday, Sep 20, 2008 ePaper | Mobile/PDA Version | Audio |
|
|
|
|
|
Marketing
-
New Products & Services Natco launches nanotech drug for breast cancer Our Bureau Hyderabad, Sept 19 Natco Pharma Ltd has launched its first nanotechnology drug, Albupax, for breast cancer treatment. It is the first generic version of the international brand Abraxane of Abraxis Biosciences, USA. Albupax contains Paclitaxel in an albumin bound nano-particle form. “It replaces the conventional Paclitaxel and has the advantage of having least side-effects. In the conventional Paclitaxel, the solvent polyethylated castor oil is used which causes severe side-effects such as neutropenia, hypersensitivity reactions and neuropathy. Albupax does not contain this solvent and, hence, can be given in optimum doses for enhanced efficacy,” the Hyderabad-based company said in a release. indigenously developedThe drug has been indigenously developed by Natco in India and is the first albumin-bound Paclitaxel in nano-particle form to be developed in the country, the release said. A 100 mg vial of Albupax would cost Rs 11,500. The estimated Indian market for this product is about Rs 150 crore. Globally, it had $375 million sales in 2007. “Natco believes that Albupax has the potential to become the single largest brand amongst its basket of oncology products. We are also exploring the possibility of a tie-up for taking this brand to international markets,” Natco added. The incidence of breast cancer is increasing in India, with nearly a lakh new patients added each year. By 2015, this is likely to increase to two lakh new cases every year, according to industry estimates. Mylan, Natco tie up to market drug Natco Pharma gets national award Natco scouting for retail chains in US USFDA nod for Natco facility Natco files another petition on Roche’s Tarceva Natco Pharma buys pharmacy store in US Natco Pharma Q3 net rises 31% Natco applies for compulsory licence on Roche’s cancer drug More Stories on : New Products & Services | Pharmaceuticals | Health
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|
